Potentially inappropriate prescriptions of antipsychotic and anticholinergic drugs in patients with Parkinson's disease.

IF 2.3 Q3 CLINICAL NEUROLOGY Neurodegenerative disease management Pub Date : 2021-10-01 Epub Date: 2021-09-16 DOI:10.2217/nmt-2021-0021

Luis Fernando Valladales-Restrepo, Nathalia Marcela Peña-Verjan, Katherine Vargas-Díaz, Jorge Enrique Machado-Alba

{"title":"Potentially inappropriate prescriptions of antipsychotic and anticholinergic drugs in patients with Parkinson's disease.","authors":"Luis Fernando Valladales-Restrepo, Nathalia Marcela Peña-Verjan, Katherine Vargas-Díaz, Jorge Enrique Machado-Alba","doi":"10.2217/nmt-2021-0021","DOIUrl":null,"url":null,"abstract":"Aim: The objective was to determine the prevalence of the potentially inappropriate antipsychotics and anticholinergics used in patients with Parkinson's disease. Materials & methods: A cross-sectional study identified the prescription of antipsychotics, anticholinergics and drugs for the treatment of Parkinson's disease. The anticholinergic burden was evaluated, and quetiapine and clozapine were considered to be adequate antipsychotics. Results: 2965 patients with Parkinson's disease were identified. The presence of psychiatric disorders and other neurological pathologies was associated with a greater probability of receiving potentially inappropriate antipsychotic prescriptions. The presence of greater number of comorbidities was associated with a greater probability of receiving anticholinergics. Conclusion: Older age and associated comorbidities, especially psychiatric and neurological comorbidities, increase the likelihood of patients with Parkinson's disease being prescribed antipsychotics and anticholinergics.","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":null,"pages":null},"PeriodicalIF":2.3000,"publicationDate":"2021-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neurodegenerative disease management","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2217/nmt-2021-0021","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/9/16 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 2

Abstract

Aim: The objective was to determine the prevalence of the potentially inappropriate antipsychotics and anticholinergics used in patients with Parkinson's disease. Materials & methods: A cross-sectional study identified the prescription of antipsychotics, anticholinergics and drugs for the treatment of Parkinson's disease. The anticholinergic burden was evaluated, and quetiapine and clozapine were considered to be adequate antipsychotics. Results: 2965 patients with Parkinson's disease were identified. The presence of psychiatric disorders and other neurological pathologies was associated with a greater probability of receiving potentially inappropriate antipsychotic prescriptions. The presence of greater number of comorbidities was associated with a greater probability of receiving anticholinergics. Conclusion: Older age and associated comorbidities, especially psychiatric and neurological comorbidities, increase the likelihood of patients with Parkinson's disease being prescribed antipsychotics and anticholinergics.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

帕金森病患者的抗精神病和抗胆碱能药物处方可能不适当。

目的:目的是确定帕金森病患者使用的潜在不适当的抗精神病药物和抗胆碱能药物的患病率。材料与方法:一项横断面研究确定了抗精神病药物、抗胆碱能药物和治疗帕金森病的药物的处方。评估了抗胆碱能负荷，喹硫平和氯氮平被认为是适当的抗精神病药物。结果:共发现2965例帕金森病患者。精神疾病和其他神经系统疾病的存在与接受潜在不适当的抗精神病药物处方的更大可能性相关。合并症的数量越多，接受抗胆碱能药物治疗的可能性越大。结论:老年和相关的合并症，特别是精神和神经系统合并症，增加了帕金森病患者服用抗精神病药物和抗胆碱能药物的可能性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Neurodegenerative disease management CLINICAL NEUROLOGY-

CiteScore

4.30

自引率

0.00%

发文量